Paper39273139
Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.
Ishikawa K and 9 others. Int J Mol Sci, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas. Papers, record 39273139. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39273139
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hyaluronan Receptors | Major topic |
| Mouth Neoplasms | Major topic |
| Antibodies, Monoclonal | Major topic |
| Xenograft Model Antitumor Assays | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Cell Line, Tumor | |
| CHO Cells | |
| Cricetulus | |
| Antineoplastic Agents, Immunological | |
| Antibody-Dependent Cell Cytotoxicity | |
| Cell Proliferation | |
| Mice, Inbred BALB C |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 24am0521010 (to Y.Kato), JP23ama121008 (to Y.Kato), JP23am0401013 (to Y.Kato), JP23bm1123027 (to Y.Kato), and JP23ck0106730 (to Y.Kato) | Japan Agency for Medical Research and Development | PubMed | ||
| 22K06995 (to H.S.), 21K20789 (to T.T.), 21K07168 (to M.K.K.), and 22K07224 (to Y.Kato) | Japan Society for the Promotion of Science | PubMed |
Source PubMed
References80
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26074915 | CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells. | Front Immunol | 2015 | https://conductscience.org/library/papers/26074915 | PubMed |
| 2 | 1707342 | A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. | Cell | 1991 | https://conductscience.org/library/papers/1707342 | PubMed |
| 3 | 37176118 | A Novel Anti-CD44 Variant 3 Monoclonal Antibody C44Mab-6 Was Established for Multiple Applications. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37176118 | PubMed |
| 4 | 23694705 | Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. | Semin Immunol | 2013 | https://conductscience.org/library/papers/23694705 | PubMed |
| 5 | 12464636 | CD44 is required for two consecutive steps in HGF/c-Met signaling. | Genes Dev | 2002 | https://conductscience.org/library/papers/12464636 | PubMed |
| 6 | 7689929 | Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. | Cancer Res | 1993 | https://conductscience.org/library/papers/7689929 | PubMed |
| 7 | 27081038 | Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. | Oncotarget | 2016 | https://conductscience.org/library/papers/27081038 | PubMed |
| 8 | 34424761 | Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method. | Monoclon Antib Immunodiagn Immunother | 2021 | https://conductscience.org/library/papers/34424761 | PubMed |
| 9 | 28923838 | Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT. | Mol Cancer Res | 2017 | https://conductscience.org/library/papers/28923838 | PubMed |
| 10 | 21187443 | Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. | J Immunol | 2011 | https://conductscience.org/library/papers/21187443 | PubMed |
| 11 | 7532175 | Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. | J Cell Biol | 1995 | https://conductscience.org/library/papers/7532175 | PubMed |
| 12 | 24607406 | CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. | Cell Stem Cell | 2014 | https://conductscience.org/library/papers/24607406 | PubMed |
| 13 | 37504249 | Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C44Mab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas. | Curr Issues Mol Biol | 2023 | https://conductscience.org/library/papers/37504249 | PubMed |
| 14 | 37185762 | A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers. | Curr Issues Mol Biol | 2023 | https://conductscience.org/library/papers/37185762 | PubMed |
| 15 | 28920587 | Complement in cancer: untangling an intricate relationship. | Nat Rev Immunol | 2018 | https://conductscience.org/library/papers/28920587 | PubMed |
| 16 | 30396933 | Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression. | Anticancer Res | 2018 | https://conductscience.org/library/papers/30396933 | PubMed |
| 17 | 11992408 | Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. | Int J Cancer | 2002 | https://conductscience.org/library/papers/11992408 | PubMed |
| 18 | 17062682 | A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/17062682 | PubMed |
| 19 | 38460519 | Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies. | Structure | 2024 | https://conductscience.org/library/papers/38460519 | PubMed |
| 20 | 24410905 | Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. | BMC Cancer | 2014 | https://conductscience.org/library/papers/24410905 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40688499 | Development of a specific anti-human EphA3 monoclonal antibody, Ea3Mab-20, for flow cytometry. | Biochem Biophys Rep | 2025 | https://conductscience.org/library/papers/40688499 | PubMed |
| 40688054 | Hyaluronic Acid-Functionalized Bismuth Vanadate/Molybdenum Disulfide Nanoheterojunctions Achieve Efficient Phototherapy of Hypoxic Tumor. | Biomater Res | 2025 | https://conductscience.org/library/papers/40688054 | PubMed |
| 40236294 | Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applications. | Biochem Biophys Rep | 2025 | https://conductscience.org/library/papers/40236294 | PubMed |
| 40028039 | A novel anti-mouse CCR7 monoclonal antibody, C7Mab-7, demonstrates high sensitivity in flow cytometry, western blot, and immunohistochemistry. | Biochem Biophys Rep | 2025 | https://conductscience.org/library/papers/40028039 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39273139
GET https://conductscience.org/api/papers/v1/39273139/references?page=2